deaths (OS)

ovarian cancer (OC) ovarian cancer (OC)

mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population

versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-4%

mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive

versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-2%

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)